Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Panacea Biotec Ltd. ('Panacea Biotec') is pleased to announce that the Company has entered into a tripartite agreement with Natco Pharma Ltd. ('Natco') and Breckenridge Pharmaceutical Inc. ('Breckenridge') for the manufacture and supply of Azacitidine Injection for the U.S. market under Breckenridge's already-approved ANDA. Azacitidine is a generic equivalent of Vidaza, which is marketed by Celgene Corporation, U.S....
27-08-2018
Bigul

Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, please find enclosed herewith newspaper copies of Extract of Statement of Un-Audited Financial Results for the quarter ended 30th June, 2018, published in the following newspapers on 15th August, 2018:- Business Standard (English); Desh Sewak (Punjabi) This is for your kind information and record please.
17-08-2018
Bigul

Fixes Book Closure for AGM

 Panacea Biotec Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 24, 2018 to September 29, 2018 (both days inclusive) for the purpose of 34th Annual General Meeting (AGM) of the Company to be held on September 29, 2018.
17-08-2018
Bigul

Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter Ended 30Th June, 2018

 We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 14.08.2018 inter-alia, considered and approved the Unaudited Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter ended 30.06.2018 in terms of Reg 33 of SEBI LODR Regulations, 2015. The same were also reviewed by the Audit Committee in its meeting held on 13.08.2018....
14-08-2018
Bigul

Outcome of Board Meeting

 The Board of the Company has, at its meeting held today, inter-alia, considered and approved the Unaudited Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter ended 30.06.2018 in terms of Reg 33 of SEBI LODR Regulations, 2015. The same were also reviewed by the Audit Committee in its meeting held on 13.08.2018....
14-08-2018
Bigul

Closure of Trading Window

 Pursuant to the Code of Conduct of the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window of the Company shall remain closed for all designated persons including promoters, directors, key managerial personnel and designated employees of the Company from 04.08.2018 to 16.08.2018 (both days inclusive).
03-08-2018
Bigul

Board Meeting Intimation for Board Meeting On 14Th August, 2018 For Approving The Unaudited Financial Results (Provisional) For The Quarter Ended 30Th June, 2018

 PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2018 ,inter alias, to consider and approve Pursuant to Reg 29 of SEBI LODR Regulations, this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 14.08.2018, inter-alia, to consider and approve the Unaudited Financial Results (Provisional) for the quarter ended 30.06.2018....
03-08-2018
Bigul

Announcement under Regulation 30 (LODR)-Demise

 We are deeply grieved to inform that Mr. O. P. Kelkar, Independent Director of the Company has departed for his heavenly abode on July 21, 2018. Accordingly, Mr. O. P. Kelkar has ceased to be director on the Board of Directors of the Company. Kindly take the above information on your record.
24-07-2018
Bigul

Shareholding for the Period Ended June 30, 2018

 Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click here
19-07-2018
Bigul

Statement Of Investor Complaints For The Quarter Ended June 2018

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- VINOD GOELDesignation :- Company Secretary and Compliance Officer
06-07-2018
Next Page
Close

Let's Open Free Demat Account